SCYNEXIS, Inc. Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate
SCYNEXIS, Inc. (SCYX) reported Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate of 0.36% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate · last filed 2021-03-29
- SCYNEXIS, Inc. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2020 was 0.36%, a 82.94% decline from fiscal 2019.
- SCYNEXIS, Inc. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2019 was 2.11%, a 13.52% decline from fiscal 2018.
- SCYNEXIS, Inc. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2018 was 2.44%, a 21.39% increase from fiscal 2017.
- SCYNEXIS, Inc. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2017 was 2.01%, a 42.55% increase from fiscal 2016.
| Period end | Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate 12 month |
|---|---|
| 2020-12-31 | 0.36% 10-K · filed 2021-03-29 |
| 2019-12-31 | 2.11% 10-K · filed 2021-03-29 |
| 2018-12-31 | 2.44% 10-K · filed 2020-03-11 |
| 2017-12-31 | 2.01% 10-K · filed 2019-03-14 |
| 2016-12-31 | 1.41% 10-K · filed 2018-03-13 |
| 2015-12-31 | 1.62% 10-K · filed 2017-03-13 |
| 2014-12-31 | 1.75% 10-K · filed 2017-03-13 |
| 2013-12-31 | 2.37% 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |